Indicated for MPAL cases harboring FLT3 mutations (particularly T/myeloid MPAL) or with FLT3 pathway overexpression (e.g., B/myeloid MPAL with ZNF384 rearrangement, MPAL with KMT2A rearrangement). This evidence concerns the gene FLT3 and mixed phenotype acute leukemia.